definiens: ), licenses of rights to as defined under Section 101(35A ) of theBankruptcy Code . The Parties agree that [COMPANY], as a licensee of such rights under this Agreement, will retain andmay fully exercise all of its rights and elections under the Bankruptcy Code . The parties further agree that that uponcommencement of a bankruptcy proceeding by or against [COMPANY] under the Bankruptcy Code, [COMPANY] will be entitledto a complete duplicate of, or complete access to ( as [COMPANY] deems appropriate ), all such intellectual property and allembodiments of such intellectual property . Such intellectual property and all embodiments of such intellectualproperty will be promptly delivered to [COMPANY] ( a ) upon any such commencement of a bankruptcy proceeding and uponwritten request by [COMPANY], unless [COMPANY] elects to continue to perform all of its obligations under this Agreement, or(b ) if not delivered under ( a ) above, upon the rejection of this Agreement by or on behalf of [COMPANY] and upon writtenrequest by the [COMPANY] . [COMPANY] ( in any capacity, including debtor - in - possession ) and its successors and assigns(including any trustee ) agrees not to interfere with the exercise by [COMPANY] or its Affiliates of its rights and licenses tosuch intellectual property and such embodiments of intellectual property in accordance with this Agreement, andagrees to assist [COMPANY] and its Affiliates in obtaining such intellectual property and such embodiments of intellectualproperty in the possession or control of Third Parties as reasonably necessary or desirable for [COMPANY] to exercisesuch rights and licenses in accordance with this Agreement . The foregoing provisions are without prejudice to anyrights [COMPANY] may have arising under the Bankruptcy Code or other applicable law . Notwithstanding the foregoing inthis Section 9.9, nothing in this Section 9.9 shall be read to entitle [COMPANY] to obtain disclosure of or access toAdimab Platform / Core Technology ( including [COMPANY] Platform / Core Technology Improvements ), whether or not as an or otherwise, at any time, and [COMPANY] shall not under any circumstances notwithstandinganything express or implied in this Agreement be entitled to disclosure of [COMPANY] Platform / Core Technology ( includingAdimab Platform / Core Technology Improvements )